Genscript Biotech logo

Genscript Biotech(SEHK) 1548

Market CapHK$79.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)+3,104%
5 Year+18%
1 Year+116%
1 Month+10%
HK$34.98
-1.63%
-0.58Today
Genscript Biotech last closing stock price
MetricPriceDate
Last closeHKD 35.562026-10-13
Genscript Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-27.64%HKD 49.142026-10-06
1 month+9.89%HKD 32.362026-09-11
3 month+139.95%HKD 14.822026-07-15
Year to date+186.31%HKD 12.422025-12-31
1 year+115.78%HKD 16.482025-10-13
3 year+64.63%HKD 21.602023-10-13
5 year+17.75%HKD 30.202021-10-12
Since inception+3,103.63%HKD 1.322015-12-30

Genscript Biotech Financials at a Glance

Market Cap

HK$79.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.67B

Net Income (TTM)

$2.48B

EPS (TTM)

-HK$2.29

P/E Ratio

-15.50

Dividend

HK$0.00

Beta (Volatility)

-0.03 (Low)

Price

HK$34.98

Volume

36,623,083

Open

HK$35.56

Previous Close

HK$35.56

Daily Range

HK$34.58 - HK$36.78

52-Week Range

HK$10.36 - HK$49.46

Estimated Earnings Date

Mar 24, 2027

1548 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genscript Biotech

Genscript Biotech Corporation is a leading provider of innovative life science research solutions, established in 2002 and headquartered in Nanjing, China. The company operates globally, offering a diverse range of products and services across various sectors, including biotechnology, pharmaceuticals, and agriculture.

Products and Services
  • Gene and oligonucleotide synthesis for research and diagnostics
  • Comprehensive biologics development services for therapeutic antibodies
  • Cell therapy solutions, including CAR-T therapies for cancer treatment
Growth Outlook
  • Revenue of 403 million USD reported in Q2 2026, indicating strong market demand
  • Operating income margin improved to 12.3% in Q2 2026
  • Continued expansion in North America and Europe enhances market presence
Financial Highlights
  • Trailing twelve months (TTM) revenue of 1.6 billion USD
  • Net income margin of -32% in Q2 2026, reflecting ongoing investment in growth
  • Cash and short-term investments totaled 831 million USD as of Q2 2026
Genscript Biotech Corporation has established itself as a key player in the biotechnology sector, focusing on innovative solutions that cater to a wide array of scientific and industrial needs. The company's diverse product offerings, including gene synthesis and biologics development, position it well for future growth. Recent financial performance indicates a robust revenue stream, with significant investments aimed at expanding capabilities and market reach. The ongoing development of advanced therapies, particularly in the cell therapy space, underscores the company's commitment to addressing critical healthcare challenges. With a solid cash position and a focus on strategic growth, Genscript Biotech Corporation presents an intriguing opportunity for potential investors interested in the biotechnology sector.
AI Generated • Oct 11, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

6,165

CEO

Weihui Shao

Website

www.genscript.com

Headquarters

Hong Kong, HK

1548 Financials

Key Financial Metrics (TTM)

Gross Margin

51.99%

Operating Margin

14.88%

Net Income Margin

-75.40%

Return on Equity

-16.23%

Return on Capital

6.05%

Return on Assets

-13.29%

Earnings Yield

-6.45%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$79.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.25B

Volume

36.62M

Avg. Volume

40.42M

Financials (TTM)

Gross Profit

$898.04M

Operating Income

$305.01M

EBITDA

$440.96M

Operating Cash Flow

$382.20M

Capital Expenditure

-$131.41M

Free Cash Flow

$250.79M

Cash & ST Invst.

$831.18M

Total Debt

$254.68M

Genscript Biotech Performance Analysis

Genscript Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 4,899,521,39828.6%
20232023-12-31USD 4,373,372,495-10.7%
20242024-12-31USD 4,675,159,8076.9%
20252025-12-31USD 7,480,503,00360.0%
Genscript Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-318.5%
Q22025-06-3067.7%
Q42025-12-31-15.0%
Q22026-06-30-8.5%
Genscript Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.85-38.3%
20232023-12-31USD -0.35-58.2%
20242024-12-31USD -0.99180.7%
20252025-12-31USD -1.9292.7%
Genscript Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31129.2%
Q22025-06-30-261.2%
Q42025-12-31-964.8%
Q22026-06-3074.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$403.25M

+41.4%

Gross Profit

$206.21M

+54.5%

Gross Margin

51.14%

N/A

Market Cap

HK$79.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$13.03M

N/A

Employees

6,135

N/A

Net Income

-$129.03M

+26.3%

EBITDA

$89.85M

+133.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$831.18M

-55.6%

Total Debt

$254.68M

-74.3%

Accounts Receivable

$156.78M

+19.9%

Inventory

$45.24M

-11.0%

Long Term Debt

$141.55M

-85.0%

Short Term Debt

$203.19M

+346.7%

Return on Assets

-13.29%

N/A

Return on Invested Capital

3.09%

N/A

Free Cash Flow

$9.10M

+116.8%

Operating Cash Flow

$56.68M

-29.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRLCharles River Laboratories International, Inc.
$299.02-0.94%
TECHBio-Techne Corporation
$72.48-0.11%
BIOBio-Rad Laboratories, Inc.
$363.73-0.19%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About 1548

What is the current price of Genscript Biotech?

Genscript Biotech is trading at HK$34.98 per share.

What is the 52-week range for Genscript Biotech?

Over the past 52 weeks, Genscript Biotech has traded between HK$10.36 and HK$49.46.

How much debt does Genscript Biotech have?

As of the most recent reporting period, Genscript Biotech reported total debt of $4.74B.

How much cash does Genscript Biotech have on hand?

Genscript Biotech reported $1.35B in cash and cash equivalents in its most recent financial results.

What is Genscript Biotech’s dividend yield?

Genscript Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services